DUXAP8 and hepatocellular carcinoma: Mechanistically, it was found that DUXAP8 upregulated MAPK1 through competitive binding to miR-584-5p, which activated the MAPK/ERK pathway and promoted the proliferation, invasive migration, stemness maintenance, and chemotherapy resistance of HCC.